Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.38 |
| ▸ | AXL | P30530 | 8/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | ACACA | Q13085 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2214697 | 0.97 | GPR119 (0.39) | GPR119HRH3AXL | |
| SCHEMBL1845766 | 0.97 | GPR119 (0.39) | GPR119HRH3AXL | |
| SCHEMBL2216051 | 0.97 | GPR119 (0.39) | GPR119HRH3AXL | |
| SCHEMBL2216602 | 0.94 | GPR119 (0.39) | GPR119HRH3AXLHDAC4HDAC6 | |
| SCHEMBL2219537 | 0.94 | AXL (0.38) | GPR119AXL | |
| SCHEMBL2221102 | 0.93 | GPR119 (0.39) | GPR119HRH3AXLHDAC4HDAC6 | |
| SCHEMBL2217715 | 0.93 | GPR119 (0.37) | GPR119HRH3AXLHDAC4HDAC6 | |
| SCHEMBL2216116 | 0.91 | GPR119 (0.38) | GPR119HRH3AXLHDAC4HDAC6 | |
| SCHEMBL2217647 | 0.90 | GPR119 (0.38) | GPR119HRH3AXLHDAC4HDAC6 | |
| SCHEMBL2217652 | 0.90 | GPR119 (0.38) | GPR119HRH3AXLHDAC4HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178054-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| US-20110178054-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| US-20110178054-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| WO-2010004348-A1 | HETEROCYCLIC GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178054-A1 | Heterocyclic GPCR Agonists | GPR119, GCGR, GPR27 | GPR119 1/4885HRH3 406/4885AXL 581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.